Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone

References

• Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. 1st ed. Lyon: IARC Press, 2002. 310–3.
   Google Scholar
• Dorfmann HD, Czerniak B. Bone Tumors. 1st ed. St Louis: Mosby, 1998. 559–98.
   Google Scholar
• Haque AU, Moatasim A. Giant cell tumor of bone: A neoplasm or a reactive condition? Int J Clin Exp Pathol 2008. 1: 489–501.
   PubMed Web of Science ®Google Scholar
• Guenther R, Krenn V, Morawietz L, et al Giant cell tumors of the bone: Molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract 2005. 201: 649–63.
   PubMed Web of Science ®Google Scholar
• Zheng MH, Robbins P, Xu J, et al The histogenesis of giant cell tumour of bone:a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001. 16: 297–307.
   PubMed Web of Science ®Google Scholar
• Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003. 97: 2520–9.
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D, et al PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005. 23: 5357–64.
   PubMed Web of Science ®Google Scholar
• de Mestier P, des Guetz G. Treatment of gastrointestinal stroma tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005. 29: 357–61.
   PubMed Web of Science ®Google Scholar
• Baselga J, Arribas J. Treating cancer's kinase ‘addiction’. Nat Med 2004. 10: 786–7.
   PubMed Web of Science ®Google Scholar
• Won Kim T, Lee H, Kang YK, et al Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004. 10: 3076–81.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Dumez H, Judson I, et al Use of c-KIT/PDGFRA mutation analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004. 40: 689–95.
   PubMed Web of Science ®Google Scholar
• Sulzbacher I, Träxler M, Mosberger I, et al Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000. 13: 632–7.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999. 79: 1283–316.
   PubMed Web of Science ®Google Scholar
• Gamberi G, Serra M, Ragazzini P, et al Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 2003. 10: 351–6.
   PubMed Web of Science ®Google Scholar
• Gamberi G, Benassi MS, Ragazzini P, et al Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone. Ann Oncol 2004. 15: 498–503.
   PubMed Web of Science ®Google Scholar
• Horvai AE, Kramer MJ, Garcia JJ, et al Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod Pathol 2008. 21: 423–30.
   PubMed Web of Science ®Google Scholar
• Cheng YY, Huang L, Kumta SM, et al Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 2003. 27: 385–91.
   PubMed Web of Science ®Google Scholar
• Cheng YY, Huang L, Lee KM, et al Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004. 75: 71–7.
   PubMed Web of Science ®Google Scholar
• Atkins GJ, Hayes DR, Graves SE, et al Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000. 15: 640–9.
   PubMed Web of Science ®Google Scholar
• Lau YS, Sabokbar A, Gibbons CL, et al Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005. 36: 945–54.
   PubMed Web of Science ®Google Scholar
• Hamdy NA. Densosumab: RANKL inhibition in the management of bone loss. Drugs Today 2008. 44: 7–21.
   PubMed Web of Science ®Google Scholar
• Morgan T, Atkins GJ, Trivett MK, et al Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor κB. Am J Pathol 2005. 167: 117–28.
   PubMed Web of Science ®Google Scholar
• Sulzbacher I, Birner P, Toma C, et al Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J Clin Pathol 2007. 60: 804–7.
   PubMed Web of Science ®Google Scholar
• Wei H, Zhao MQ, Dong W, et al Expression of c-kit protein and mutation status of the c-kit gene in osteosarcoma and their clinicopathological significance. Int Med Res 2008. 36: 1008–14.
   PubMed Web of Science ®Google Scholar
• Kuba T, Piperdi S, Rosenblum J, et al Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008. 112: 2119–29.
   PubMed Web of Science ®Google Scholar
• Entz-Werle N, Gaub MP, Lavaux T, et al KIT gene in pediatric osteosarcomas: could it be a new therapeutic target? Int J Cancer 2007. 120: 2510–6.
   PubMed Web of Science ®Google Scholar